Home / Intelligence / Case Studies / Improving Targeting Precision and Field Force Direction through AIML-based Patient Finding
Background
- A global rare disease company was looking to improve targeting precision and support field team effectiveness
- Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria
- Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified
- Given the small number of patients in each indication, every new start is high value, both for the lives of patients in need and for the commercial success of the therapies
Trinity’s Solution
- Create an AIML model that identifies clinically on-label patients—rather than simply patients with the disease
- ‘Learn’ from on-therapy patients to identify how patients present prior to therapy initiation and execute AIML models to flag patients based on the probability that they are candidates for treatment
- Deploy bifurcated notifications to both inside and field-based reps through ‘push’ alerts within the client’s CRM and enable ‘pull’ solutions to support call planning
- Success drivers include:
- Data acumen to evaluate and select source data
- Therapeutic area expertise
- Deep collaboration with Medical to refine and calibrate models
- AIML experience to optimize feature selection and approach
Project Outcomes
Designed and deployed AIML models for three indications in 8 weeks
Narrowed field team focus from >25,000 HCPs to ~1,000 highest priority HCPs
Identified 100 high probability targets within first 2 months of launch
At least 5 patients confirmed to be clinically on-label for therapy within first 2 months
First new patient enrolled within 5 weeks of initiating alerts
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.
Related Intelligence
Webinars
The GenAI Advantage: Empowering Pharma Customer-Facing Teams
June 11, 2025 | 1:00 – 1:45 PM ET
Additional sessions will be offered on:June 12 – 12:00 (UTC +8:00) – Asia/ShanghaiJune 12 – 12:00 CET – Europe/Berlin Join us for the first webinar in our “AI Innovations in Life Sciences” series to learn how generative AI (GenAI) can transform the way customer-facing teams (sales reps and medical science liaisons) operate in life sciences […]
Sign Up Now
White Papers
Technology with a Point of View: Encoding Life Sciences Expertise with AI
As an industry, life sciences is now looking towards technological change to leverage investments made during the past few years. In fact, according to Trinity’s TGaS Advisors, the proportion of surveyed companies reporting that they have completed proof of concept or are using GenAI at an enterprise level for commercial, medical, or customer operations surged […]
Read More
Blog
Operationalizing Generative AI in Life Sciences—Trinity Life Sciences Included in Everest Group Report
The transformative potential of generative AI (GenAI) within the life sciences industry is highlighted in Everest Group’s report, “AI-deas to Action: Operationalizing Generative AI in Life Sciences.” Fifteen companies were selected for inclusion across three categories: To be included in the report, providers had to have been profiled in past Everest Group PEAK Matrix® […]
Read More